naphthoquine   Click here for help

GtoPdb Ligand ID: 10396

Antimalarial Ligand
Compound class: Synthetic organic
Comment: Naphthoquine is a 4-aminoquinoline antimalarial compound.
The marketed formulations contain naphthoquine phosphate (PubChem CID 9851774).

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 57.18
Molecular weight 409.19
XLogP 5.83
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES Clc1ccc2c(c1)nccc2Nc1cc(CNC(C)(C)C)c(c2c1CCCC2)O
Isomeric SMILES Clc1ccc2c(c1)nccc2Nc1cc(CNC(C)(C)C)c(c2c1CCCC2)O
InChI InChI=1S/C24H28ClN3O/c1-24(2,3)27-14-15-12-22(17-6-4-5-7-18(17)23(15)29)28-20-10-11-26-21-13-16(25)8-9-19(20)21/h8-13,27,29H,4-7,14H2,1-3H3,(H,26,28)
No information available.
Summary of Clinical Use Click here for help
Naphthoquine does not have FDA or EMA approval but in combination with artemisinin (trade name ARCO®) is one of the new artemisinin-based combination therapies (ACTs) registered and used in a number of countries but not yet recommended by the WHO [4]. A Phase 4 trial to evaluate ARCO® for the treatment of uncomplicated P. falciparum malaria in adults and children has been completed (NCT01930331).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01930331 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Phase 4 Interventional Ifakara Health Institute